Vijaya Iyer is a freelance science writer for BioNews Services. She has contributed content to their several disease-specific websites, including cystic fibrosis, multiple sclerosis, muscular dystrophy, among others.
She holds a PhD in Microbiology from Kansas State University, where her research focused on molecular biology, bacterial interactions, metabolism, and animal models to study bacterial infections. Following the completion of her PhD, Dr. Iyer went on to complete three postdoctoral fellowships at Kansas State University, University of Miami and Temple University.
She joined BioNews Services to utilize her scientific background and writing skills to help patients and caregivers remain abreast with important scientific breakthroughs.
Differences in molecular events in the gut contribute to the disrupted microbiome and flare-ups in patients with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, according to a ... Read more
OSE Immunotherapeutics’ therapeutic candidate OSE-127 for chronic inflammatory bowel disease (IBD) showed anti-inflammatory activity in a study performed in mice and patients’ samples. The study, “IL-7 receptor influences anti-TNF responsiveness ... Read more
Women with Crohn’s disease are at a higher risk for mood disorders (depression and anxiety) and substance abuse issues after giving birth than those without inflammatory bowel disease (IBD), Canadian ... Read more
Men with a history of Crohn’s disease or ulcerative colitis may be more prone to prostate cancer than those without any inflammatory bowel disease, a review study suggests. The study “Inflammatory ... Read more
People diagnosed with depression have a higher risk of Crohn’s disease and ulcerative colitis, but taking antidepressants may protect against the development of these inflammatory bowel diseases, a British study reports. ... Read more
The levels of a molecule named microRNA-31 may serve as indicators of disease severity and progression in adults and children with Crohn’s disease (CD). “For such a clinically heterogenous [with ... Read more
Allergan recently announced two new clinical trials to the test the efficacy of its investigational therapy, Brazikumab, for treatment of two forms of inflammatory bowel disease. The two clinical trials, INTREPID ... Read more
Healthcare workers with inflammatory bowel disease (IBD) develop tuberculosis at a higher rate than non-healthcare workers with IBD, but this trend does not extend to other types of severe infection, ... Read more